News 2024-03-02
Porton Pharma Solutions Joined the SBTi to Drive Climate Action
Porton Pharma Solutions Ltd. is thrilled to announce its commitment to climate action by joining the Science Based Targets initiative (SBTi). By aligning our emissions reduction targets with the Paris Agreement goals on limiting global warming to 1.5°C, we aim to contribute towards creating a sustainable and low-carbon future.
By joining the SBTi, Porton commits to setting ambitious, science-based greenhouse gas (GHG) emissions reduction near term targets in line with the goals outlined in the Paris Agreement. These targets will be developed using the most up-to-date climate science available and will ensure that our emissions trajectory is consistent with the global effort to limit temperature rise below dangerous levels.
"We are excited to join the SBTi and commit to science-based targets, which remarks another milestone in Porton’s actions to mitigate climate change, " said Oliver Ju, Chairman of Porton. "By doing so, we are taking concrete actions to address climate change and contribute to the global collective effort. In 2023, we established a task force to comprehensively advance and implement our initiatives concerning climate change. We believe that businesses have a crucial role in leading the transition to a sustainable future, and we are committed to doing our part."
As part of our commitment to the SBTi, Porton will regularly measure and report our progress towards our targets, providing transparency and accountability to our stakeholders. Through this process, we will identify opportunities for innovation and efficiency, promoting sustainable practices throughout our operations and supply chain.
About SBTi
The Science Based Targets initiative (SBTi) is a partnership between CDP, the United Nations Global Compact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF), aiming to drive ambitious climate action in the private sector by enabling organizations to set science-based emissions reduction targets.
Others
MoreNews 2024-10-31
Milestone | Comprehensive Enhancement of GMP Manufacturing Capacity and New Modality Service Capabilities at Porton Fengxian, Shanghai
Recently, Porton Pharma has achieved a significant capacity breakthrough at its GMP manufacturing facility in Fengxian, Shanghai, China, further enhancing its production capabilities and technological strength in new modality areas such as peptide and oligonucleotide drugs. This upgrade represents an important step in Porton's commitment to becoming a leading global CDMO company.
News 2024-10-24
Porton Pharma Solutions Signed Strategic Partnership with Shanghai InnoStar
On October 24, 2024, Porton Pharma SolutionsLtd. ("Porton") announced a strategic partnership with Shanghai InnoStar Bio-tech Co., Ltd. ("InnoStar") in Shanghai. The distinguished signing ceremony was attended by Mr. Ju Nianfeng, Chairman and CEO of Porton; Dr. Chang Yan, President of InnoStar; Ms. Pi Wei, Deputy General Manager of Porton; Ms. Fan Meng, Deputy General Manager of the Sales & Marketing Center, Dr. Fang Xin, Senior Director of Non-clinicalPharmacology BU at InnoStar, and Ms. Zhao Jie, Marketing Associate Director at InnoStar.